Open Access
Issue
Med Buccale Chir Buccale
Volume 18, Number 3, août 2012
Page(s) 181 - 185
Section Articles originaux / Original articles
DOI https://doi.org/10.1051/mbcb/2012020
Published online 05 July 2012
  1. Frampton JE. Cetuximab: a review of its use in squamous cell carcinoma of the head and neck. Drugs 2012;70:1987-2010. [CrossRef] [Google Scholar]
  2. Bonner JA, Harari PM, Giralt J, Arzania N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78. [CrossRef] [PubMed] [Google Scholar]
  3. Pryor DI, Porceddu SV, Burmeister BH, Guminski A, Thomson DB, Shepherdson K, Poulsen M. Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer. Radiother Oncol 2009;90:172-6. [CrossRef] [PubMed] [Google Scholar]
  4. De Arruda FF, Puri DR, Zhung J, Narayana A, Wolden S, Hunt M, Stambuk H, Pfister D, Kraus D, Shaha A, Shah J, Lee NY. Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: the Memorial Sloan-Kettering Cancer Center experience. Int J Radiat Oncol Biol Phys 2006;64:363-73. [CrossRef] [PubMed] [Google Scholar]
  5. Sonis ST, Peterson DE, McGuire DB, Williams DA. Prevention of mucositis in cancer patients. J Natl Cancer Inst Monogr 2001;29:1-2. [CrossRef] [PubMed] [Google Scholar]
  6. Lord HK, Junor E, Ironside J. Cetuximab is effective but more toxic than reported in the Bonner trial. Clin Oncol 2008;20:96. [CrossRef] [PubMed] [Google Scholar]
  7. Walsh L, Gillham C, Dunne M, Fraser I, Hollywood D, Armstrong J, Thirion P. Toxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell carcinoma. Radiot Oncol 2011;98:38-41. [CrossRef] [Google Scholar]
  8. Tejwani A, Shenhong W, Yuxia J, Agulnik M, Millender L, Lacouture ME. Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy. Cancer 2009;115:1286-99. [CrossRef] [PubMed] [Google Scholar]
  9. Birnbaum AE, Johnson TT, Rathore R, Khurshid H, Puthawala M, Radie Keane K, Ruhl C, Wanebo H, Kennedy T, Ready N, BrUOG. Induction cetuximab (C) followed by C, paclitaxel (P), carboplatin (CP) and concurrent radiation (RT) for locoregionally advanced squanmous cell carcinoma of the head and neck (SCCHN) [abstract]. 2007 ASCO Annual Meeting Proceedings. J Clin Oncol 2007;25(Suppl.):16504. [Google Scholar]
  10. Harari PM, Harris J, Kies MS, Myers JN, Machtay M, Rotman MZ, Khontia D, Straube WL, Ang KK. Phase II randomized trial of surgery followed by radiochemotherapy plus cetuximab for high-risk squamous cell carcinoma of the head and neck (RTOG 9234) [abstract]. Int J Radiat Oncol Biol Phys 2007;69(Suppl.);S13. [Google Scholar]
  11. Suntharalingam M, Taylor R, Wolf J, Cullen K, Zimrin A, Ord R, Kataria R, Strome S. Early toxicity and response data from a phase II trial of weekly cetuximab, CBDCA, paclitaxel, and daily RT in patients with locally advanced SCCHN. Int J Radiat Oncol Biol Phys 2007;69(Suppl.);S432-3. [CrossRef] [Google Scholar]
  12. Argiris A, Karamouzis MV, Smith R, Kotsakis A, Gibson MK, Lai SY, Kim S, Branstetter BF, Shuai Y, Romkes M, Wang L, Grandis JR, Ferris RL, Johnson JT, Heron DE. Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in head and neck cancer. Ann Oncol 2011;22:2482-8. [CrossRef] [PubMed] [Google Scholar]
  13. Robert F, Ezekiel MP, Spencer SA, Bonner JA, Khazaeli MB, Saleh MN, Carey D, LoBuglio AF, Cooper MR, Waksal HW. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001;19:3234-43. [PubMed] [Google Scholar]
  14. Alongi F, Bignardi M, Garassino I, Pentimalli S, Cavina R, Mancosu P, Reggiori G, Poletti A, Ferrari D, Foa P, Bigoni A, Dragonetti A, Salvatori P, Spahiu O, Fogliata A, Cozzi L, Santoro A. Scorsetti M. Prospective phase II trial of cetuximab plus VMAT-SIB in locally advanced head and neck squamous cell carcinoma: feasibility and tolerability in elderly and chemotherapy-ineligible patients. Strahlender Onkol 2012;188:49-55. [Google Scholar]
  15. Trotti A, Bellm LA, Epstein JB, Frame D, Fuchs HJ, Gwede CK, Komaroff E, Nalysyk L, Zilberberg MD. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol 2003;66:253-62. [CrossRef] [PubMed] [Google Scholar]
  16. Lacouture ME, Anadkat MJ, Bensadoun RJ, Bryce J, Chan A, Epstein JB, Eaby-Sandy B, Murphy BA, MASCC Skin Toxicity Study Group. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care cancer 2011;19:1079-95. [CrossRef] [PubMed] [Google Scholar]
  17. Cheng KK, Leung SF, Liang RH, Tai JW, Yeung RM, Thompson DR. Severe oral mucositis associated with cancer therapy: impact on oral functional status and quality of life. Support Care Cancer 2010;18:1477-85. [CrossRef] [PubMed] [Google Scholar]
  18. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for locoregionally advances head and neck cancer: 5-year survival data from a phase 3 randomized trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11:21-8. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.